Related Experiment Video

Updated: Mar 21, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Taxanes in the Treatment of Advanced Gastric Cancer

Byung Woog Kang1, Oh-Kyoung Kwon2, Ho Young Chung3

  • 1Department of Oncology/Hematology, Kyungpook National University Medical Center, Kyungpook National University School of Medicine, Kyungpook National University Cancer Research Institute, 807 Hogukno, buk-gu, Daegu 41404, Korea. bwkang@knu.ac.kr.

Molecules (Basel, Switzerland)
|May 20, 2016
PubMed

Insights

Taxanes, including paclitaxel and docetaxel, show antitumor activity for advanced gastric cancer (AGC). This review examines their effectiveness and side effects in first- and second-line chemotherapy for AGC patients.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Advanced gastric cancer (AGC) remains a significant global health challenge, being the second leading cause of cancer mortality worldwide.
  • Despite treatment advances, AGC prognosis requires continuous improvement.
  • Taxanes (paclitaxel, docetaxel) are established chemotherapeutic agents targeting microtubule stabilization and cell division.

Purpose of the Study:

  • To review the efficacy and tolerability of taxane-based chemotherapy in advanced gastric cancer.
  • To evaluate taxanes in both first-line and second-line treatment settings for AGC.

Main Methods:

  • Systematic review of clinical studies on taxane chemotherapy for AGC.
  • Analysis of data on treatment response, survival rates, and adverse events associated with taxanes.

Main Results:

  • Taxanes demonstrate significant antitumor activity in AGC treatment.
  • Efficacy and tolerability profiles vary depending on the specific taxane and treatment line (first- or second-line).

Conclusions:

  • Taxanes represent a valuable therapeutic option for advanced gastric cancer.
  • Further research may optimize taxane-based regimens for improved patient outcomes and reduced toxicity.
Keywords:
chemotherapydocetaxelgastric cancerpaclitaxeltaxanes

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.9K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
786
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
726
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K